文献速递功能神经外科

磁共振引导聚焦超声苍白球毁损术治疗帕金森病的疗效与局限:一项Ⅰ期临床试验

The efficacy and limits of magnetic resonance-guided focused ultrasound pallidotomy for Parkinson's disease: a Phase I clinical trial.
PubMed 文献 · J Neurosurg · 2018-08-10

该前瞻性、非随机、单臂Ⅰ期临床试验于2013年12月至2016年5月在单一三级医疗中心纳入10例药物难治性、以运动障碍为主的帕金森病患者,行单侧磁共振引导聚焦超声苍白球毁损术。8例(80%)成功完成并随访超过6个月,6个月随访时「关期」UPDRS第三部分评分改善32.2%(p=0.018)、UDysRS改善52.7%(p=0.017),1年随访分别改善39.1%(p=0.046)和42.7%(p=0.046),伴生活质量改善;1例出现与超声照射相关的不寻常副作用,无患者遗留持续性后遗症。作者认为该技术有效,但存在因技术问题导致热毁损不完全的局限,需进一步研究和长期随访验证。

要点

  • 单侧MRgFUS苍白球毁损术在8/10例(80%)药物难治性帕金森病运动障碍患者中成功实施。
  • 6个月随访「关期」UPDRS第三部分评分改善32.2%(p=0.018),UDysRS改善52.7%(p=0.017)。
  • 1年随访「关期」UPDRS第三部分评分改善39.1%(p=0.046),UDysRS改善42.7%(p=0.046)。

核心结论

  • 作者在本首项单侧MRgFUS苍白球毁损术治疗帕金森病运动障碍的Ⅰ期先导研究中证实了该毁损术的有效性,并指出因技术问题导致热毁损不完全而不可避免存在一定局限。
  • 作者认为需进一步研究和长期随访以验证MRgFUS在临床实践中的应用。

研究设计与样本

  • 前瞻性、非随机、单臂Ⅰ期临床试验,于2013年12月至2016年5月在单一三级医疗中心开展。
  • 纳入10例药物难治性、以运动障碍为主的帕金森病患者,签署书面知情同意后使用Exablate 4000装置(InSightec)行单侧MRgFUS苍白球毁损术。
  • 按1年随访方案连续评估运动改善、神经心理效应和不良事件;主要指标为基线至1周、1个月、3个月、6个月和1年的UPDRS与UDysRS评分变化,次要指标为神经心理成套测验和SF-36生活质量问卷,并监测研究期间所有事件以评估技术失败与安全性问题。

主要发现

  • 单侧MRgFUS苍白球毁损术在10例中8例(80%)成功实施,患者随访超过6个月。
  • 6个月随访时「关期」UPDRS第三部分评分较基线改善32.2%(p=0.018),UDysRS较基线改善52.7%(p=0.017)。
  • 1年随访时「关期」UPDRS第三部分评分较基线改善39.1%(p=0.046),UDysRS较基线改善42.7%(p=0.046)。
  • 上述结果伴随生活质量改善。
  • 8例中1例出现与超声照射相关的不寻常副作用,但无患者出现持续性后遗症。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出因技术问题导致热毁损不完全而不可避免地存在一定局限。
  • 作者认为需进一步研究和长期随访以验证MRgFUS在临床实践中的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Recently, MR-guided focused ultrasound (MRgFUS) has emerged as an innovative treatment for numerous neurological disorders, including essential tremor, Parkinson's disease (PD), and some psychiatric disorders. Thus, clinical applications with this modality have been tried using various targets. The purpose of this study was to determine the feasibility, initial effectiveness, and potential side effects of unilateral MRgFUS pallidotomy for the treatment of parkinsonian dyskinesia. METHODS: A prospective, nonrandomized, single-arm clinical trial was conducted between December 2013 and May 2016 at a single tertiary medical center. Ten patients with medication-refractory, dyskinesia-dominant PD were enrolled. Participants underwent unilateral MRgFUS pallidotomy using the Exablate 4000 device (InSightec) after providing written informed consent. Patients were serially evaluated for motor improvement, neuropsychological effects, and adverse events according to the 1-year follow-up protocol. Primary measures included the changes in the Unified Parkinson's Disease Rating Scale (UPDRS) and Unified Dyskinesia Rating Scale (UDysRS) scores from baseline to 1 week, 1 month, 3 months, 6 months, and 1 year. Secondary measures consisted of neuropsychological batteries and quality of life questionnaire (SF-36). Technical failure and safety issues were also carefully assessed by monitoring all events during the study period. RESULTS: Unilateral MRgFUS pallidotomy was successfully performed in 8 of 10 patients (80%), and patients were followed up for more than 6 months. Clinical outcomes showed significant improvements of 32.2% in the "medication-off" UPDRS part III score (p = 0.018) and 52.7% in UDysRS (p = 0.017) at the 6-month follow-up, as well as 39.1% (p = 0.046) and 42.7% (p = 0.046) at the 1-year follow-up, respectively. These results were accompanied by improvement in quality of life. Among 8 cases, 1 patient suffered an unusual side effect of sonication; however, no patient experienced persistent aftereffects. CONCLUSIONS: In the present study, which marks the first Phase I pilot study of unilateral MRgFUS pallidotomy for parkinsonian dyskinesia, the authors demonstrated the efficacy of pallidal lesioning using MRgFUS and certain limitations that are unavoidably associated with incomplete thermal lesioning due to technical issues. Further investigation and long-term follow-up are necessary to validate the use of MRgFUS in clinical practice.Clinical trial registration no.: NCT02003248 (clinicaltrials.gov).

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Jung NY, Park CK, Kim M, et al. The efficacy and limits of magnetic resonance-guided focused ultrasound pallidotomy for Parkinson's disease: a Phase I clinical trial. J Neurosurg. 2018. PMID: 30095337. doi:10.3171/2018.2.JNS172514

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。